BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
Want to see BBIO full AI Analyst Report?
BBIO Stock Chart & Stats
$76.75
-$0.10(-0.35%)
At close: 4:00 PM EST
$76.75
-$0.10(-0.35%)
Day’s Range― - ―
52-Week Range$31.77 - $84.94
Previous CloseN/A
Volume379.31K
Average Volume (3M)1.78M
Market Cap
$13.92B
Enterprise Value$15.91B
Total Cash (Recent Filing)$587.48M
Total Debt (Recent Filing)$2.73B
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding195,806,240
10 Day Avg. Volume1,626,700
30 Day Avg. Volume1,781,667
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)-7.27
Price to Sales (P/S)30.05
P/FCF Ratio-33.75
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue31.69
Enterprise Value/Gross Profit33.58
Enterprise Value/Ebitda-25.56
Forecast
1Y Price Target
$105.00Price Target Upside36.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-1.91
Revenue Forecast (FY)$917.67M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe FORTIFY pivotal study met its pre-specified primary and secondary endpoints with a favorable safety profile, supporting BBP-418's potential as a disease-modifying treatment for limb-girdle muscular dystrophy.
Commercial AdoptionSustained prescription growth for Attruby and physician preference versus existing therapy indicate meaningful uptake in transthyretin cardiomyopathy and support the franchise's revenue potential.
Pipeline Value And FinancingMultiple late-stage programs and the potential to secure a Priority Review Voucher could provide non-dilutive capital and broaden the company's commercial portfolio beyond a single launch.
Bears Say
Generic Competition RiskInvestor concern about potential generic tafamidis competition could create a market overhang and weigh on the stock through uncertainty about future market share.
Pricing PressurePossible generic entry may reduce pricing power in the disease area, which could lower revenue per patient and compress profit margins for marketed therapies.
Regulatory Execution RiskRegulatory approvals depend on the timing and outcome of agency interactions, introducing execution risk that could delay product launches and expected cash flow improvements.
BridgeBio Pharma News
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $31.77 and its highest was $84.94 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
BridgeBio Pharma Inc’s market cap is $13.92B.
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Jul 30, 2026 which is in 88 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
Currently, no data Available
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 195,806,240 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Currently, no hedge funds are holding shares in BBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$105.00 (36.81% Upside)
$105.00 (36.81% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.60%
12-Months-Change
Fundamentals
Return on Equity
39.18%
Trailing 12-Months
Asset Growth
1.82%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
BBIO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive outlook driven by robust commercial momentum for Atruby, multiple positive Phase 3 readouts (notably infigratinib in achondroplasia), improving cash runway via convertible notes, and a clear path to becoming cash-generative by 2028. These progress points materially de-risk the pipeline and support substantial future value creation. Near-term headwinds include a sizable SG&A and operating expense ramp as the company builds commercial infrastructure, continued net cash consumption during the scale-up phase, concentrated current revenue in one product, and external IP/legal uncertainty around tafamidis that has contributed to share-price volatility. Overall, the positives (strong revenue growth, multiple successful late-stage readouts, solid balance sheet actions, and clear launch plans) outweigh the lowlights, though execution and legal risks remain.View all BBIO earnings summariesBBIO Stock 12 Month Forecast
Average Price Target
$105.00
▲(36.81% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Moderna
―
Ownership Overview
20.28% Insiders
24.50% Mutual Funds
0.86% Other Institutional Investors
39.98% Public Companies and Individual Investors